Opthea Appoints Company Secretary and Vice President of Finance
14. Juni 2021 07:00 ET
|
Opthea Limited
MELBOURNE, Australia, June 14, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors
01. Juni 2021 07:11 ET
|
Opthea Limited
Board expands strengths in clinical and commercialization strategy OPT-302 pivotal Phase 3 trials for wet age-related macular degeneration (AMD) on track to reporting top-line data in 2023 ...
Opthea Company Secretary Resignation
06. April 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of...
Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD
31. März 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD
15. März 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, March 15, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference
10. März 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Finalizes Study Designs and Start-up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD
24. Februar 2021 05:30 ET
|
Opthea Limited
Following consultations with US FDA and EU EMA, two pivotal Phase 3 clinical trial designs are finalized to assess 2 mg OPT-302 administered 4-weekly or 8-weekly in combination with Lucentis® (ShORe...
Opthea to Present at the 10th Annual SVB Leerink Global Healthcare Conference
17. Februar 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Announces Pricing of Initial Public Offering in the United States
16. Oktober 2020 11:20 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Announces Launch of Proposed Initial Public Offering in the United States
11. Oktober 2020 20:00 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 11, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...